Cargando…
Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
PURPOSE: Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well to initial therapy, resistance eventually develops, and thus, mo...
Autores principales: | Hammer, Stefanie, Schlicker, Andreas, Zitzmann-Kolbe, Sabine, Baumgart, Simon, Hagemann, Urs B., Scholz, Arne, Haendler, Bernard, Lejeune, Pascale, Karlsson, Jenny, Ellingsen, Christine, Hennekes, Hartwig, Nielsen, Carsten H., Juul, Mark U., Mumberg, Dominik, Schatz, Christoph A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401501/ https://www.ncbi.nlm.nih.gov/pubmed/34035067 http://dx.doi.org/10.1158/1078-0432.CCR-21-0342 |
Ejemplares similares
-
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy
por: Hagemann, Urs B., et al.
Publicado: (2020) -
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021) -
Targeted thorium-227 conjugates as treatment options in oncology
por: Karlsson, Jenny, et al.
Publicado: (2023) -
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies
por: Zitzmann-Kolbe, Sabine, et al.
Publicado: (2023) -
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)